At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
ruxolitinib phosphate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
In Brief
A Phase 2 clinical trial evaluating ruxolitinib phosphate, danazol, and 2 other interventions for Anemia and 2 related conditions. Completed, enrolled 14 participants across 2 sites.
Detailed Summary
This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Primary Myelofibrosis, Secondary Myelofibrosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartApr 2013
Primary CompletionJul 2016
Study CompletionAug 2017
TodayJul 2026
First PostedNov 22, 2012
Enrollment StartApr 1, 2013
Primary CompletionJul 14, 2016
Study CompletionAug 10, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.6 years ago
Interventions
ruxolitinib phosphatedrug
Given PO
danazoldrug
Given PO
quality-of-life assessmentother
Ancillary studies
questionnaire administrationother
Ancillary studies